Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010, Article ID 368467, 11 pages
http://dx.doi.org/10.1155/2010/368467
Review Article

The Role of Peroxisome Proliferator-Activated Receptor β/δ on the Inflammatory Basis of Metabolic Disease

Department of Pharmacology and Therapeutic Chemistry, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Faculty of Pharmacy, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain

Received 20 May 2010; Accepted 28 June 2010

Academic Editor: Marcelo Napimoga

Copyright © 2010 Teresa Coll et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The pathophysiology underlying several metabolic diseases, such as obesity, type 2 diabetes mellitus, and atherosclerosis, involves a state of chronic low-level inflammation. Evidence is now emerging that the nuclear receptor Peroxisome Proliferator-Activated Receptor (PPAR) ameliorates these pathologies partly through its anti-inflammatory effects. PPAR activation prevents the production of inflammatory cytokines by adipocytes, and it is involved in the acquisition of the anti-inflammatory phenotype of macrophages infiltrated in adipose tissue. Furthermore, PPAR ligands prevent fatty acid-induced inflammation in skeletal muscle cells, avoid the development of cardiac hypertrophy, and suppress macrophage-derived inflammation in atherosclerosis. These data are promising and suggest that PPAR ligands may become a therapeutic option for preventing the inflammatory basis of metabolic diseases.